Table 2.
Clinical outcomes of overall COVID-19 patients with or without thymosin α1 treatment.
| Clinical outcomes | Non-thymosin α1 group (n = 1,976) | Thymosin α1 group (n = 306) | p |
|---|---|---|---|
| Primary outcome | |||
| Non-recovery, n (%) | 290 (14.6) | 65 (21.2) | 0.003 |
| Secondary outcomes | |||
| In-hospital mortality, n (%) | 271 (13.7) | 62 (20.2) | 0.003 |
| ICU admission, n (%) | 287 (14.5) | 42 (13.7) | 0.711 |
| Intubation, n (%) | 106 (5.3) | 31 (10.1) | 0.001 |
| Acute respiratory distress syndrome, n (%) | 499 (25.2) | 104 (33.9) | <0.001 |
| Acute kidney injury, n (%) | 66 (3.3) | 26 (8.4) | <0.001 |
| Duration of mechanical ventilation (days) | 6.2 ± 4.8 | 6.7 ± 4.2 | 0.644 |
| Length of ICU stay (days) | 8.7 ± 8.2 | 14.9 ± 12.7 | <0.001 |
| Length of hospital stay (days) | 13.8 ± 7.9 | 12.1 ± 8.2 | <0.001 |
ICU, intensive care unit.